FDA Current Good Manufacturing Practice for Drugs: What 21 CFR Parts 210 and 211 Require

Current Good Manufacturing Practice (CGMP) regulations for pharmaceutical products are the foundation of FDA drug quality assurance. Codified in 21 CFR Parts 210 and 211, these regulations establish minimum requirements for the methods, facilities, and controls used in the manufacturing, processing, packing, and holding of drug products. For foreign drug manufacturers seeking to export to the United States, CGMP compliance is not optional — it is a legal requirement that the FDA actively enforces through facility inspections, Warning Letters, import alerts, and criminal prosecution. A drug product manufactured in a facility that does not comply with CGMP is considered adulterated under Section 501(a)(2)(B) of the FD&C Act, regardless of whether the product itself meets its quality specifications.

Organization and personnel requirements

21 CFR 211.22 requires that there be a quality control unit within the drug manufacturing organization that has the authority to approve or reject all components, drug products, production and control procedures, labeling, and packaging materials. The quality control unit must review and approve all production and control records to determine compliance with established procedures before a batch is released for distribution. The regulation also requires that personnel engaged in manufacturing, processing, packing, or holding of a drug product have the education, training, and experience to perform their assigned functions, and that training be conducted regularly and documented.

Buildings and facilities

21 CFR 211.42 through 211.58 establish requirements for buildings and facilities used in drug manufacturing. Buildings must be of suitable size, construction, and location to facilitate cleaning, maintenance, and proper operations. There must be adequate space for orderly placement of equipment and materials to prevent mix-ups between different components, drug products, or labeling. Specific areas must be designated for receiving, quarantine, storage, manufacturing, packaging, labeling, and quality control operations. Lighting, ventilation, air filtration, heating, and cooling systems must be adequate to protect the drug product from contamination. Plumbing must be adequate to prevent contamination, and sewage and refuse must be disposed of in a safe and sanitary manner. For sterile drug products, additional environmental controls — including HEPA filtration, laminar airflow, and environmental monitoring — are required.

Equipment and production controls

Equipment used in the manufacture, processing, packing, or holding of a drug product must be of appropriate design, adequate size, and suitably located to facilitate operations, cleaning, and maintenance (21 CFR 211.63). Equipment must be constructed so that surfaces that contact components, drug products, or in-process materials are not reactive, additive, or absorptive so as to alter the safety, identity, strength, quality, or purity of the drug product. Equipment must be cleaned, maintained, and sanitized at appropriate intervals, and written procedures must be established and followed for the cleaning and maintenance of equipment. Production and process controls (21 CFR 211.100 through 211.115) require written procedures for production and process control, designed to ensure that the drug products have the identity, strength, quality, and purity they are represented to possess.

Laboratory controls and testing

21 CFR 211.160 through 211.176 establish requirements for laboratory controls. These include testing and release procedures to determine that each lot of drug product conforms to appropriate specifications before release for distribution, including identity testing of each active ingredient, strength testing, purity testing, and testing for other quality attributes as specified in the product's specifications. Stability testing programs (21 CFR 211.166) must be established to assess the stability of drug products and to determine appropriate storage conditions and expiration dates. Reserve samples of each lot of drug product must be retained for at least one year after the expiration date of the lot (21 CFR 211.170). Laboratory records must be complete and accurate, and out-of-specification (OOS) results must be investigated and documented.

Records and reports

CGMP requires extensive documentation. Master production and control records (21 CFR 211.186) must be prepared for each drug product and must include the complete formula, component specifications, production procedures, in-process controls, and packaging specifications. Batch production and control records (21 CFR 211.188) must be prepared for each batch and must document that each step in the production and control process was followed. Distribution records (21 CFR 211.196) must facilitate the recall of any lot of drug product. Complaint records (21 CFR 211.198) must be maintained, and any complaint involving the possible failure of a drug product to meet its specifications must be investigated. All records must be retained for at least one year after the expiration date of the batch.

FDA enforcement of CGMP at foreign facilities

The FDA inspects foreign drug manufacturing facilities and issues Form FDA 483 observations when CGMP deviations are found. If the facility's response to the 483 is inadequate, the FDA may issue a Warning Letter, and persistent non-compliance can result in import alerts that block all products from the facility. Import Alert 66-40 is used for drug products from firms with significant CGMP violations. FDA inspections of foreign facilities increased significantly under FSMA and GDUFA, and the agency also conducts Remote Regulatory Assessments (RRAs) as a supplement to on-site inspections. Foreign manufacturers should maintain inspection readiness at all times, with current SOPs, complete batch records, and trained personnel available to accompany FDA investigators.

How FDABridge supports drug manufacturing compliance

FDABridge provides drug establishment registration and drug product listing services for foreign drug manufacturers. While CGMP compliance requires ongoing operational commitment at the facility level, FDABridge ensures that your regulatory filings with the FDA are current and accurate — the administrative foundation that supports your facility's compliance posture. Visit fdabridge.com/drug to see our drug registration services or fdabridge.com/contact to discuss your needs.